Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
PILL ETF Declines -13% Over 30 Days Amid Pharma Sector Pressure

PILL ETF Declines -13% Over 30 Days Amid Pharma Sector Pressure

Key Takeaways

  • PILL fell roughly 13% over the trailing 30 days as weakness in U.S. pharmaceutical stocks was magnified by the fund's 3x daily leverage.
  • The broader three-month trend shows a steeper decline, with PILL down approximately 43% amid ongoing pressure in the pharmaceuticals sub-industry.
  • As a daily-reset leveraged product, PILL targets 300% of the daily return of the S&P Pharmaceuticals Select Industry Index, amplifying both gains and losses.
  • The fund uses a modified equal-weighted approach, so its roughly 75 holdings each carry modest weight with no single stock dominating performance.
  • Daily rebalancing introduces volatility drag that can erode value in choppy markets and compound losses during sustained declines.
  • Primary drivers include sector-wide selling in pharmaceuticals, regulatory and drug-pricing uncertainty, and elevated short-term swings in smaller biopharma names.
  • For additional context on valuation and outlook, explore Price Targets and Forecast pages for PILL.
  • Discover AI-driven trading strategies by browsing Trending AI Robots.

Understanding PILL's Structure and Holdings

The Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL) seeks daily investment results, before fees and expenses, equal to 300% of the performance of the S&P Pharmaceuticals Select Industry Index. That index serves as a modified equal-weighted benchmark for stocks within the S&P Total Market Index classified under the pharmaceuticals sub-industry of the Global Industry Classification Standard (GICS).

PILL holds roughly 75 underlying pharmaceutical names and operates as a non-diversified fund that obtains its leverage primarily through swap agreements and other financial instruments rather than direct borrowing. Because the index is equal-weighted, top holdings such as Axsome Therapeutics (AXSM), Eli Lilly (LLY), Merck (MRK), and Viatris (VTRS) each represent only about 2% of the index. The fund carries a net expense ratio of roughly 0.97% and maintains a relatively small asset base, with assets under management in the low tens of millions of dollars.

This structure helps explain much of PILL's recent behavior. With exposure spread across small-, mid-, and large-cap pharmaceutical companies and leverage reset daily, the fund tends to show outsized short-term volatility compared to a standard sector fund, especially when the underlying index moves sharply.

PILL Price Performance: Recent 30 Days Versus the Quarter

Over the trailing 30 days, PILL declined approximately 13%, moving from a closing price near $15.08 to about $13.08. The path was choppy rather than steady, with the fund ranging between roughly $13.40 and $17.99 before giving back gains into the latest close. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The three-month picture looks considerably weaker. PILL fell about 43% over the last quarter, dropping from a level near $22.82 to $13.08. This shows that the recent 30-day decline forms part of a longer downtrend rather than an isolated move, which aligns with a leveraged product tracking an index under sustained selling pressure.

Factors Behind PILL's Moves in the Last 30 Days

The main driver of PILL's decline is the performance of the underlying S&P Pharmaceuticals Select Industry Index, amplified by 3x daily leverage. When the benchmark falls, PILL's daily reset mechanism magnifies those losses, and repeated down days erode value more than a simple cumulative index move would indicate.

The equal-weighted design also plays a role. Smaller, higher-beta biopharma and specialty pharmaceutical names receive the same weighting as larger, more stable firms, making the index more sensitive to shifts in risk appetite. Weakness in these more volatile constituents contributed to broader drawdowns in the benchmark, which PILL then magnified threefold on a daily basis.

Macro conditions added further pressure. Ongoing scrutiny of drug pricing and healthcare policy, along with shifting investor preferences away from defensive sectors during risk-on periods, weighed on the pharmaceuticals group. Elevated interest-rate expectations can also affect longer-duration growth-oriented biopharma names, contributing to the choppy price action seen in PILL.

Drivers of PILL's Performance Over the Quarter

The quarterly decline reflects a broader rotation out of pharmaceutical equities that has continued for several months. Investors have favored other sectors and themes, while regulatory uncertainty around drug pricing and Medicare negotiation has remained a structural overhang.

Because PILL is a daily-reset leveraged product, the longer the underlying index stays under pressure or trades in a volatile range, the more pronounced the negative compounding effect becomes. This helps explain why the fund's quarterly loss of roughly 43% exceeds a simple three-times multiple of the index's own decline. Institutional flows out of leveraged pharmaceutical exposure have also kept average trading volumes modest, reflecting reduced conviction in the sector over the period.

What to Watch for PILL Going Forward

Looking ahead, several factors are likely to influence PILL's path. The most important remains the direction of the underlying pharmaceutical index, since leverage will continue to amplify daily moves in either direction. Investors should monitor policy developments around drug pricing and healthcare regulation, which have repeatedly shaped sector sentiment, as well as earnings results from major index constituents.

Interest-rate expectations and broader risk appetite will also matter, particularly for the smaller, higher-beta biopharma names that carry outsized influence in an equal-weighted benchmark. Finally, because PILL resets exposure daily, holding-period volatility and the risk of compounding losses remain structural considerations that warrant attention. These themes, rather than any single data point, are likely to drive the fund's behavior in the months ahead.

Exploring AI Tools for Sector Analysis

In my own research, I often turn to Tickeron's AI-powered platforms to scan for patterns and compare holdings across leveraged ETFs like PILL. These tools help surface relevant signals in the underlying pharmaceuticals names without replacing careful fundamental review. For investors focused on thematic or leveraged products, they can provide an efficient way to cross-check momentum and volatility metrics alongside traditional analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PILL

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for PILL turns negative, indicating new downward trend

PILL saw its Momentum Indicator move below the 0 level on November 20, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 75 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for PILL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

PILL moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PILL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

PILL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PILL's RSI Oscillator exited the oversold zone, 28 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for PILL crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PILL advanced for three days, in 288 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 199 of 213 cases where PILL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) ETF is 54.42B. The market cap for tickers in the group ranges from 31.04M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is EYPT at 31.04M.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) ETF was -20%. For the same ETF, the average monthly price growth was -12%, and the average quarterly price growth was 7%. CRMD experienced the highest price growth at 13%, while RLMD experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) ETF was 54%. For the same stocks of the ETF, the average monthly volume growth was 19% and the average quarterly volume growth was 30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 51
Price Growth Rating: 54
SMR Rating: 73
Profit Risk Rating: 71
Seasonality Score: 6 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.